Sıvı kondensatlar içinde alfa-sinüklein agregasyonunun farmakolojik inhibisyonu

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

Abstract Aggregated forms of α-synuclein constitute the major component of Lewy bodies, the proteinaceous aggregates characteristic of Parkinson’s disease1,2. Emerging evidence suggests that α-synuclein aggregation may occur within liquid condensates formed through phase separation3-5. This mechanism of aggregation creates new challenges and opportunites for drug discovery for Parkinson’s disease, which is otherwise still incurable6. Here we show that the condensation-driven aggregation pathway of α-synuclein can be inhibited using small molecules. We report that the aminosterol claramine stabilizes α-synuclein condensates, and inhibits α-synuclein aggregation within the condensates both in vitro and in a Caenorhabditis elegans model of Parkinson’s disease. By using a chemical kinetics approach, we show that the mechanism of action of claramine is to inhibit primary nucleation within the condensates. These results illustrate a possible therapeutic route based on the inhibition of protein aggregation within condensates, a phenomenon likely to be relevant in other neurodegenerative disorders.

İlgili konular